What Do Analysts Have to Say About Gilead Sciences (GILD) Post Earnings?

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best immunotherapy stocks to buy according to hedge funds. Gilead Sciences, Inc. (NASDAQ:GILD) announced its fiscal Q4 and full year 2025 results on February 10, reporting a strong year marked by the continued growth of Biktarvy and Descovy, along with the successful launch of Yeztugo, the world’s first twice-yearly HIV prevention therapy in the country.

Gilead Sciences, Inc. (NASDAQ:GILD) also reported that the total fiscal Q4 revenues rose 5% to $7.9 billion compared to the prior year period, driven primarily by the increased sales of HIV and Liver Disease products and partially offset by lower sales of Veklury®.

Following the release, Gilead Sciences, Inc. (NASDAQ:GILD) received rating updates from several analysts. Needham and Scotiabank both released bullish rating updates for the company on February 11, with Needham raising the price target on the stock to $170 from $140 while maintaining a Buy rating, and Scotiabank lifting the price target to $177 from $140 and keeping an Outperform rating on the shares.

The same day, BofA also lifted the price target on Gilead Sciences, Inc. (NASDAQ:GILD) to $162 from $154, maintaining a Buy rating on the shares and telling investors in a post-earnings note that it is confident in 2026 growth for the company due to solid fiscal Q4 dynamics. It added that it no longer models Yeztugo cannibalization of Descovy sales in 2026.

Gilead Sciences, Inc. (NASDAQ:GILD) is a biotech company that advances medicines to prevent and treat serious diseases such as cancer, immunodeficiency virus (HIV), viral hepatitis, and COVID-19. Its portfolio of drugs focuses on medical areas with unmet needs, and includes AmBisome, Atripla, Biktarvy, Cayston, Complera, and others.

While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.